CY1124034T1 - ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p - Google Patents
ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-pInfo
- Publication number
- CY1124034T1 CY1124034T1 CY20211100361T CY211100361T CY1124034T1 CY 1124034 T1 CY1124034 T1 CY 1124034T1 CY 20211100361 T CY20211100361 T CY 20211100361T CY 211100361 T CY211100361 T CY 211100361T CY 1124034 T1 CY1124034 T1 CY 1124034T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alzheimer
- antibody
- delaying
- onset
- disease
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000000178 monomer Substances 0.000 abstract 3
- 230000009260 cross reactivity Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124034T1 true CY1124034T1 (el) | 2022-05-27 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100361T CY1124034T1 (el) | 2009-06-29 | 2021-04-27 | ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (da) |
| EP (2) | EP3892633A1 (da) |
| JP (3) | JP2012532094A (da) |
| AU (1) | AU2010267640B2 (da) |
| CA (1) | CA2765602C (da) |
| CY (1) | CY1124034T1 (da) |
| DK (1) | DK2448968T3 (da) |
| ES (1) | ES2864049T3 (da) |
| HR (1) | HRP20210611T1 (da) |
| HU (1) | HUE053949T2 (da) |
| LT (1) | LT2448968T (da) |
| PL (1) | PL2448968T3 (da) |
| PT (1) | PT2448968T (da) |
| SI (1) | SI2448968T1 (da) |
| SM (1) | SMT202100237T1 (da) |
| WO (1) | WO2011001366A1 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| ATE492561T1 (de) | 2006-03-23 | 2011-01-15 | Bioartic Neuroscience Ab | Verbesserte protofibrilselektive antikörper und deren verwendung |
| HUE038313T2 (hu) | 2010-02-26 | 2018-10-29 | Bioarctic Neuroscience Ab | Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban |
| SG192805A1 (en) | 2011-03-16 | 2013-09-30 | Probiodrug Ag | Diagnostic antibody assay |
| HRP20210680T1 (hr) | 2014-07-10 | 2021-06-11 | Bioarctic Ab | POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL |
| CN107849125A (zh) | 2015-07-21 | 2018-03-27 | 生命北极神经科学公司 | 用于治疗靶向聚集的肽的创伤性脑损伤的方法 |
| MA45684A (fr) | 2016-07-14 | 2019-05-22 | Bioarctic Neuroscience Ab | Protéine d'apport du cerveau |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CA3107370A1 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| JP2022523333A (ja) | 2019-01-30 | 2022-04-22 | トゥルーバインディング，インコーポレイテッド | 抗ｇａｌ３抗体およびその使用 |
| US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| MX2022016005A (es) | 2020-06-26 | 2023-02-02 | Bioarctic Ab | Anticuerpos de fijacion a protofibrillas de \03b1-sinucleina. |
| US20250163135A1 (en) | 2021-07-09 | 2025-05-22 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| KR20240053620A (ko) | 2021-08-30 | 2024-04-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 |
| KR20240142535A (ko) | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
| TW202440628A (zh) | 2022-12-22 | 2024-10-16 | 瑞典商生物極公司 | 新抗體 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU6524500A (en) * | 1999-08-04 | 2001-03-05 | Northwestern University | Amyloid beta protein (globular assembly and uses thereof) |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| AU2003250102B2 (en) * | 2002-07-24 | 2009-09-17 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| EP2374817B1 (en) * | 2004-04-13 | 2017-09-06 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| ATE492561T1 (de) * | 2006-03-23 | 2011-01-15 | Bioartic Neuroscience Ab | Verbesserte protofibrilselektive antikörper und deren verwendung |
| KR101377535B1 (ko) * | 2007-11-16 | 2014-03-27 | 더 락커펠러 유니버시티 | 원섬유 형태의 베타아밀로이드 단백질에 대해 특이적인 항체 |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
-
2010
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017197531A (ja) | 2017-11-02 |
| PT2448968T (pt) | 2021-04-30 |
| AU2010267640A1 (en) | 2012-01-19 |
| ES2864049T3 (es) | 2021-10-13 |
| AU2010267640B2 (en) | 2015-03-05 |
| EP3892633A1 (en) | 2021-10-13 |
| DK2448968T3 (da) | 2021-04-12 |
| CA2765602C (en) | 2021-05-25 |
| JP6884025B2 (ja) | 2021-06-09 |
| LT2448968T (lt) | 2021-05-10 |
| WO2011001366A1 (en) | 2011-01-06 |
| EP2448968A1 (en) | 2012-05-09 |
| US20120100129A1 (en) | 2012-04-26 |
| US20230295283A1 (en) | 2023-09-21 |
| SI2448968T1 (sl) | 2021-07-30 |
| HUE053949T2 (hu) | 2021-08-30 |
| JP2019218362A (ja) | 2019-12-26 |
| JP2012532094A (ja) | 2012-12-13 |
| HRP20210611T1 (hr) | 2021-05-28 |
| PL2448968T3 (pl) | 2021-09-13 |
| SMT202100237T1 (it) | 2021-05-07 |
| EP2448968B1 (en) | 2021-01-27 |
| CA2765602A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124034T1 (el) | ΑΝΤΙΣΩΜΑΤΑ ΕΚΛΕΚΤΙΚΑ ΓΙΑ ΠΡΩΤΟΪΝΙΔΙΑ/ΟΛΙΓΟΜΕΡΗ Ν-ΤΕΡΜΑΤΙΚΟΥ ΑΚΡΟΥ ΠΕΡΙΚΟΜΜΕΝΟΥ ΑΜΥΛΟΕΙΔΟΥΣ-p | |
| CY1121209T1 (el) | Αντισωματα και εμβολια προς χρηση σε θεραπευτικες και διαγνωστικες μεθοδους για σχετιζομενες με αλφα-συνουκλεϊνη διαταραχες | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CY1120267T1 (el) | Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας | |
| CY1119751T1 (el) | Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3 | |
| CY1118928T1 (el) | Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους | |
| CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
| CY1115316T1 (el) | Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| CY1119376T1 (el) | Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1115927T1 (el) | Αντισωματα εναντιον της κολοβωμενης παραλλαγης ctf-611 του her2 | |
| DK1981981T3 (da) | Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter | |
| CY1109143T1 (el) | Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας | |
| CY1115798T1 (el) | Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2 | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
| CY1118918T1 (el) | Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης |